+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation



Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation



Heart 102(24): 1969-1973



Percutaneous left atrial appendage (LAA) occlusion has been developed as a viable option for stroke and thromboembolism prevention in patients with non-valvular atrial fibrillation (NVAF) and at high risk for cerebral cardioembolic events. Data on device implantation and long-term follow-up from large cohorts are limited. 110 consecutive patients with NVAF and contraindications to oral anticoagulants (OACs) underwent LAA occlusion procedures and achieved a longer than 1 year follow-up. All patients were enrolled in a prospective registry. Procedures were performed using the Amplatzer Cardiac Plug or Amulet guided by fluoroscopy and intracardiac echocardiography. Mean age of the population was 77±6 years old; 68 were men. Atrial fibrillation was paroxysmal in 20%, persistent in 15.5% and permanent in 64.5% of cases, respectively. Mean CHA2DS2-VASc and HAS-BLED scores were 4.3±1.3 and 3.4±1, respectively. Technical success (successful deployment and implantation of device) was achieved in 100% of procedures. Procedural success (technical success without major procedure-related complications) was achieved in 96.4%, with a 3.6% rate of major procedural complications (three cases of pericardial tamponade requiring drainage and one case of major bleeding). Mean follow-up was 30±12 months (264 patient-years). Annual rates for ischaemic stroke and for other thromboembolic events were respectively 2.2% and 0%, and annual rate for major bleeding was 1.1%. Our data suggest LAA occlusion in high-risk patients with NVAF not suitable for OACs is feasible and associated with low complication rates as well as low rates of stroke and major bleeding at long-term follow-up.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058206624

Download citation: RISBibTeXText

PMID: 27492943

DOI: 10.1136/heartjnl-2015-309150


Related references

Comparison of left atrial appendage function in patients with idiopathic atrial fibrillation, valvular and non-valvular atrial fibrillation Impact on the thromboembolic risk. European Heart Journal 20(ABSTR Suppl. ): 226, 1999

ABO blood groups: A risk factor for left atrial and left atrial appendage thrombogenic milieu in patients with non-valvular atrial fibrillation. Thrombosis Research 156: 45-50, 2017

Nonvalvular atrial fibrillation in high-hemorrhagic-risk patients: state of the art of percutaneous left atrial appendage occlusion. Journal of Cardiovascular Medicine 20(1): 1-9, 2019

Transcatheter patch occlusion of the left atrial appendage using surgical adhesives in high-risk patients with atrial fibrillation. Journal of the American College of Cardiology 58(21): 2236-2240, 2011

Safety and Efficacy of Left Atrial Appendage Closure with the Amplatzer Cardiac Plug in Very High Stroke and Bleeding Risk Patients with Non-Valvular Atrial Fibrillation. Cardiology and Therapy 4(2): 167-177, 2015

Left atrial appendage occlusion in patients with atrial fibrillation and high risk of fall: a clinical dilemma or a budgetary issue?. Clinical Research in Cardiology 108(12): 1406-1407, 2019

Left atrial appendage occlusion for prevention of thromboembolic events in patients with non-valvular atrial fibrillation: closing the door to hell. Archives of Cardiovascular Diseases 105(12): 619-622, 2012

Kidney function stratified outcomes of percutaneous left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk. Acta Cardiologica 2019: 1-9, 2019

Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. Eurointervention 11(10): 1188-1194, 2016

Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion. Europace 16(5): 626-630, 2014

Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 105(16): 1887-1889, 2002

Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy. Eurointervention 12(17): 2075-2082, 2017

Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. Jacc. Cardiovascular Interventions 2(7): 594-600, 2009

Elevated homocysteine increases the risk of left atrial/left atrial appendage thrombus in non-valvular atrial fibrillation with low CHA2DS2-VASc score. Europace 20(7): 1093-1098, 2018

Left atrial appendage occlusion in valvular atrial fibrillation following MitraClip implantation. Clinical Research in Cardiology 101(5): 393-396, 2012